Middle East Respiratory Syndrome {MERS} – Pipeline Review: Autoimmune Technologies LLC, Gilead Sciences Inc

A new independent 51 page research with title ‘Middle East Respiratory Syndrome {MERS} – Pipeline Review, H2 2017’  guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions and important players/vendors such as Autoimmune Technologies LLC, Gilead Sciences Inc, Inovio Pharmaceuticals Inc, NanoViricides Inc, Novavax Inc With n-number of tables and figures examining the Middle East Respiratory Syndrome, the research gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2022

Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/872008-middle-east-respiratory-syndrome-mers-pipeline-review

Middle East Respiratory Syndrome (MERS) – Pipeline Review, H2 2017

The latest Pharmaceutical and Healthcare disease pipeline guide Middle East Respiratory Syndrome (MERS) – Pipeline Review, H2 2017, provides an overview of the Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline landscape.

Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Middle East Respiratory Syndrome (MERS) – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 8 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Middle East Respiratory Syndrome (MERS) (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned in the Report

Autoimmune Technologies LLC
Gilead Sciences Inc
Inovio Pharmaceuticals Inc
NanoViricides Inc
Novavax Inc
Phelix Therapeutics LLC
Regeneron Pharmaceuticals Inc
Romark Laboratories LC

Request a sample report @ https://www.htfmarketreport.com/sample-report/872008-middle-east-respiratory-syndrome-mers-pipeline-review

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Middle East Respiratory Syndrome (MERS) – Overview
Middle East Respiratory Syndrome (MERS) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Middle East Respiratory Syndrome (MERS) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Middle East Respiratory Syndrome (MERS) – Companies Involved in Therapeutics Development
Autoimmune Technologies LLC
Gilead Sciences Inc
Inovio Pharmaceuticals Inc
NanoViricides Inc
Novavax Inc
Phelix Therapeutics LLC
Regeneron Pharmaceuticals Inc
Romark Laborator

….Continued

Connect with us at
https://www.linkedin.com/company/13388569/
https://plus.google.com/u/0/+Htfmarketreportinsights
https://www.facebook.com/htfmarketintelligence/  
https://twitter.com/htfmarketreport